The Outcomes Research Program has the following four specific aims: 1) Evaluate the outcomes of cancer, including health-related quality of life, in a broad range of health care settings 2) Assess the effectiveness and costs of new &established interventions to prevent, detect and treat cancer 3) Identity determinants of the quality of cancer care 4) Characterize barriers to optimal care with a special focus on racial, ethnic and socioeconomic disparities in cancer care and approaches to eliminate disparities in care To achieve these objectives, the Program has assembled a multi-disciplinary group of investigators with demonstrated expertise in the methods of health services research and a proven commitment to the study of cancer outcomes. Their research spans the continuum from basic methodological studies, through clinical applications, to policy applications. The Program was originally funded in 2000 when Dana-Farber/Harvard Cancer Center was established, and it was rated as """"""""outstanding"""""""" in the last renewal in 2005. The Program is led by J. Ayanian(BWH) and J.Weeks(DFCI) and currently has 54 members from 11 HMS departments and three HSPH departments with representation from all seven member institutions. In 2009, Program members were awarded $14.2 million in research funding (total costs), which includes over $9 million in NCI funding and $2.8 million in other federal peer-reviewed funding. The total number of publications from members of the Program during the project period (2006 to 2010) was 1,055. Ofthese 17% ofthese were intra-programmatic collaborations, 33% were inter-programmatic, and 24% were inter-institutional.
The Outcomes Research Program focuses on enhancing the effectiveness and cost-effectiveness of interventions to prevent, diagnose and treat cancer and its consequences. The primary focus is on evaluating interventions that optimize patient-oriented outcomes, identifying barriers to optimal care of all patients, defining approaches to eliminate these barriers, and ensuring that society's resources are allocated effectively to achieve those goals.
|Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303|
|Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296|
|Yao, Lina; Seaton, Sarah Craven; Ndousse-Fetter, Sula et al. (2018) A selective gut bacterial bile salt hydrolase alters host metabolism. Elife 7:|
|Jalbut, Marla M; Brunner, Andrew M; Amrein, Philip C et al. (2018) Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma 59:988-991|
|Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187|
|Roemer, Margaretha G M; Redd, Robert A; Cader, Fathima Zumla et al. (2018) Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950|
|Francini, Edoardo; Gray, Kathryn P; Xie, Wanling et al. (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78:889-895|
|Hu, Yanhui; Vinayagam, Arunachalam; Nand, Ankita et al. (2018) Molecular Interaction Search Tool (MIST): an integrated resource for mining gene and protein interaction data. Nucleic Acids Res 46:D567-D574|
|Mohr, Stephanie E; Rudd, Kirstin; Hu, Yanhui et al. (2018) Zinc Detoxification: A Functional Genomics and Transcriptomics Analysis in Drosophila melanogaster Cultured Cells. G3 (Bethesda) 8:631-641|
|Odiaka, Emeka; Lounsbury, David W; Jalloh, Mohamed et al. (2018) Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP). J Glob Oncol :1-12|
Showing the most recent 10 out of 411 publications